人間の血小板機能阻害剤の構造とタンパク質設計

Jiayin Dai¹, Jie Liu, Yiqun Deng

¹Department of Biochemistry, Weill Medical College of Cornell University, New York, NY 10021, USA.

Cell

|March 10, 2004

まとめ

血性関節動物は,血小板活性化を防ぐために唾液アピラーゼを使用します. 研究者はヒトのアピラゼを設計し,潜在的抗血栓治療のためにその活動を100倍に高めました.

科学分野:

バイオケミストリーバイオケミストリー
構造生物学構造生物学とは
薬理学薬理学とは

背景:

血性関節足類の唾液アピラゼは,ADPを分解することによって血小板活性化を阻害する.
ADPは,損傷した細胞から放出される,血小板の集積の重要な媒介です.

研究の目的:

人間の溶解アピラゼのX線結晶構造を決定する.
酵素の基質結合部位と活性部位を理解するために.
抗血栓剤の応用のために,ADPアゼの活性が強化されたヒトアピラーゼを設計する.

主な方法:

X線結晶学を用いて,アポ状態と基板結合状態のヒトアピラゼの構造を取得した.
比較構造生物学のアプローチは,酵素の再設計のために使用されました.
ADPaseの活性と血小板の集積抑制を測定した.

主要な成果:

結晶構造は,5刃のベータプロペラ・ニュクレオチド結合ドメイン,基板結合決定因子,そしてユニークなカルシウム結合部位を明らかにした.
エンジニアリングされたヒトアピラゼは,ADPアゼの活性が100倍以上増加したことを示した.
強化された酵素は,血小板の集約を強力に抑制しました.

結論:

人間のアピラゼに対する構造的な洞察は,酵素工学を容易にする.
エンジニアリングされたアピラゼは,新しい抗血栓剤としての大きな可能性を示しています.
この研究は,血栓性疾患の新たな治療法への道を開くかもしれない.

さらに関連する動画

11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

12.3K

10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.5K

関連する概念動画

01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

1.5K

01:18

Structure and Function of Platelets

5.2K

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...

5.2K

01:22

Formation of the Platelet Plug

10.7K

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

10.7K

01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.4K

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

2.4K

01:16

Clot Retraction and Fibrinolysis

10.2K

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.